Virtual screening of low molecular weight mushrooms compounds as potential Mdm2 inhibitors

In some human cancer cases, the activity of p53 is inhibited by over-expressed Mdm2. The Mdm2 acts as an ubiquitin ligase, resulting in p53 ubiquitination and subsequent p53 proteasomal degradation. The disruption of the Mdm2-p53 interaction using small-molecule inhibitors is recognized as a promising strategy for anti-cancer drug design. Mushrooms are an important source of powerful compounds with anti-tumour properties. In this study, the first virtual screening of low molecular weight compounds present in mushroom is presented as potential Mdm2 inhibitors. A re-docking and cross-docking method was used to validate the virtual screening protocol. The steroids: ganoderic acids X (Ki = 16nM), Y (Ki = 22nM) and F (Ki = 69nM); 5,6-epoxy-24(R)-methylcholesta-7,22-dien-3β-ol (Ki = 74nM) and polyporenic acid C (Ki = 59nM) stand out as the top ranked potential inhibitors of Mdm2. The docking pose of the most promising compounds were carefully analysed and the information provided shows several interesting starting points for further development of Mdm2 inhibitors.

[1]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[2]  M. Noble,et al.  Understanding Small‐Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy , 2011, Chemical biology & drug design.

[3]  A. Herráez,et al.  Cytotoxic action of Ganoderma lucidum on interleukin‐3 dependent lymphoma DA‐1 cells: involvement of apoptosis proteins , 2011, Phytotherapy research : PTR.

[4]  J. Ungwitayatorn,et al.  Molecular docking study on anticancer activity of plant-derived natural products , 2010, Medicinal Chemistry Research.

[5]  Rui M. V. Abreu,et al.  MOLA: a bootable, self-configuring system for virtual screening using AutoDock4/Vina on computer clusters , 2010, J. Cheminformatics.

[6]  M. Vasconcelos,et al.  Wild mushrooms Clitocybe alexandri and Lepista inversa: in vitro antioxidant activity and growth inhibition of human tumour cell lines. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[7]  M. Vasconcelos,et al.  Compounds from wild mushrooms with antitumor potential. , 2010, Anti-cancer agents in medicinal chemistry.

[8]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[9]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[10]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[11]  Brian C Grieb,et al.  Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. , 2008, International journal of molecular medicine.

[12]  Paul Brazhnik,et al.  HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery). , 2007, Mathematical biosciences.

[13]  G. Hedjaroude,et al.  Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). , 2007, International immunopharmacology.

[14]  R. Paterson,et al.  Ganoderma - a therapeutic fungal biofactory. , 2006, Phytochemistry.

[15]  Avram Hershko,et al.  The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle (Nobel lecture). , 2005, Angewandte Chemie.

[16]  U. Lindequist,et al.  The Pharmacological Potential of Mushrooms , 2005, Evidence-based complementary and alternative medicine : eCAM.

[17]  L. Kan,et al.  Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. , 2005, Life sciences.

[18]  Michel F Sanner,et al.  A component-based software environment for visualizing large macromolecular assemblies. , 2005, Structure.

[19]  S. Wasser,et al.  Medicinal mushroom modulators of molecular targets as cancer therapeutics , 2005, Applied Microbiology and Biotechnology.

[20]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[21]  M. Gershwin,et al.  Mushrooms, Tumors, and Immunity: An Update , 2004, Experimental biology and medicine.

[22]  Alessandro Pedretti,et al.  VEGA – An open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming , 2004, J. Comput. Aided Mol. Des..

[23]  Guillermina Lozano,et al.  MDM2, an introduction. , 2003, Molecular cancer research : MCR.

[24]  Wei Gu,et al.  Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. , 2003, Current opinion in cell biology.

[25]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[26]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[27]  J. Bok,et al.  Antitumor sterols from the mycelia of Cordyceps sinensis. , 1999, Phytochemistry.

[28]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[29]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[30]  S. Rapior,et al.  Biological and pharmacological activity of higher fungi: 20-year retrospective analysis , 2006 .

[31]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[32]  M. Hochstrasser.  Ubiquitin-dependent protein degradation. , 1996, Annual review of genetics.